{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic&page=3", "query": { "condition": "Adenocarcinoma, Pancreatic", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1301, "total_pages": 131, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma%2C+Pancreatic&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T13:44:39.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00041808", "title": "Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastases, Neoplasm", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Pancreatic Neoplasms", "Breast Neoplasms", "Melanoma", "Sarcoma", "Gastrointestinal Neoplasms", "Lung Neoplasms", "Liver Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "MTC-DOX for Injection", "type": "DRUG" }, { "name": "Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "FeRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2001-07", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Temple, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041808" }, { "nct_id": "NCT02244489", "title": "Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Momelotinib (MMB)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-11-05", "completion_date": "2017-04-05", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244489" }, { "nct_id": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Gall Bladder Cancer", "Breast Cancer", "Neuroendocrine Tumors", "Ovarian Cancer", "Pancreatic Adenocarcinoma", "Soft Tissue Sarcoma", "Vulvar Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tivozanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 29, "start_date": "2021-12-07", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05000294" }, { "nct_id": "NCT05239182", "title": "9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-01-26", "completion_date": "2024-02-04", "has_results": true, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 2, "location_summary": "Fairway, Kansas • Pittsburgh, Pennsylvania", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239182" }, { "nct_id": "NCT03678883", "title": "9-ING-41 in Patients With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Pancreatic Cancer", "Sarcoma", "Renal Cancer", "Refractory Cancer", "Refractory Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Pancreatic Adenocarcinoma", "Resistant Cancer", "Neoplasm Metastasis", "Neoplasm of Bone", "Neoplasm, Breast", "Neoplasm of Lung", "Neoplasms,Colorectal", "Neoplasms Pancreatic", "Malignant Glioma", "Malignancies", "Malignancies Multiple", "Bone Metastases", "Bone Neoplasm", "Bone Cancer", "Pancreas Cancer", "Pancreatic Neoplasms", "Breast Neoplasms", "Acute T Cell Leukemia Lymphoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Gemcitabine - 21 day cycle", "type": "DRUG" }, { "name": "Doxorubicin.", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Carboplatin.", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Gemcitabine - 28 day cycle", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-01-04", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03678883" }, { "nct_id": "NCT05604560", "title": "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "SX-682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lei Zheng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-11-08", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 2, "location_summary": "Baltimore, Maryland • San Antonio, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05604560" }, { "nct_id": "NCT04025216", "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Triple Negative Breast Cancer", "Multiple Myeloma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "CART-TnMUC1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-10-10", "completion_date": "2022-12-02", "has_results": false, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04025216" }, { "nct_id": "NCT06518538", "title": "Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Stage IV" ], "interventions": [ { "name": "CPI-613, modified Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cornerstone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2024-08-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518538" }, { "nct_id": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma", "Nasopharyngeal Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer" ], "interventions": [ { "name": "P-MUC1C-ALLO1 CAR-T cells", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2022-02-15", "completion_date": "2039-04", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 14, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 11 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239143" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-21T13:44:39.275Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" } ] }